Dominik Höchli
Net worth: 20 021 $ as of 30/05/2026
Net worth: 20 021 $ as of 30/05/2026
Currently, Dominik Höchli is an Independent Non-Executive Director at Molecular Partners AG since 2021 and a Director at Abivax SA starting in 2025.
Formerly, Dr. Höchli was Co-Managing Director at Catapult Therapeutics BV from 2021 to 2025 and Vice President & Head-Global Medical Affairs at AbbVie AG.
Education includes a doctorate from the University of Bern.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 30/12/2025 | 4,982 ( 0.01% ) | 20 021 $ | 30/05/2026 |
| Companies | Position | Start |
|---|---|---|
| MOLECULAR PARTNERS AG | Director/Board Member | 20/04/2021 |
| ABIVAX | Director/Board Member | 21/04/2025 |
| Companies | Position | End |
|---|---|---|
Catapult Therapeutics BV
Catapult Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Operates as a biopharmaceutical company which develops cancer treatments | Chief Executive Officer | 21/04/2025 |
AbbVie AG
AbbVie AG Miscellaneous Commercial ServicesCommercial Services Develops and markets therapies | Chief Tech/Sci/R&D Officer | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
University of Bern
University of Bern Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Molecular Partners AG
Molecular Partners AG BiotechnologyHealth Technology Engages in discovery, development and commercialization of biopharmaceutical products | Health Technology |
AbbVie AG
AbbVie AG Miscellaneous Commercial ServicesCommercial Services Develops and markets therapies | Commercial Services |
Abivax SA
Abivax SA Pharmaceuticals: OtherHealth Technology Operates biotechnology company which develops therapeutics that harness the body’s natural regulatory mechanisms | Health Technology |
Catapult Therapeutics BV
Catapult Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Operates as a biopharmaceutical company which develops cancer treatments | Commercial Services |
Select your edition
All financial news and data tailored to specific country editions